What is NeoNeuro?

NeoNeuro SAS is a French company focused on the application of aptamer technology to improved treatment and diagnosis of Alzheimer's disease. NeoNeuro is a joint venture created between ICM in Paris and NeoVentures Biotechnology Inc. (Canada) that combines the neurological expertise and facilities of ICM with the innovative aptamer technologies developed by NVB. NeoNeuro has employees working within their laboratory in the ICM iPEPS incubator facility.

Why aptamers?

AD therapeutics have been unsuccessful to date. Reasons for this failure include, the difficulty associated with brain-blood-barrier penetration, the deleterious stimulation of an already chronic immune response with antibody based treatments, and a lack of stratification of patient samples. *Aptamers allow us to circumvent all three of these constraints.* NeoNeuro has developed a proprietary platform for the pre-selection of random aptamer sequences that can penetrate the blood brain barrier. These BBB Ready libraries are then used for the selection of aptamers against relevant human AD targets, such as beta-amyloid and pTau. Aptamers mimic antibodies only in their ability to bind to target molecules. Aptamers do not mimic antibodies in their capacity to stimulate an immune response. Our strategy has been to target aptamers at inhibition of protein aggregation. An innovative new diagnostic approach pioneered by NeoNeuro leads the way towards clear and deep stratification of patients on the basis of shared or contrasting pathogenic epitopes. A handful of biomarkers will not suffice for adequate patient stratification for diseases of aging. Our deep data approach to this problem will be a game changer.

What has been achieved?

- BBB Ready aptamers that inhibit aggregation of key AD proteins in vitro

-Demonstration of novel biomarker platform for AD characterization

What is NeoNeuro doing next?

We are preparing for our first pre-clinical trials of our pT231 aptamers in PS19 transgenic mice. We are also focused on the extension and validation of our Aptatype AD diagnosis platform. We intend to be in the market providing patient analyses with this deep data approach to AD with predictions of cognitive decline before the end of 2017.

Investment Opportunity:

NeoNeuro is looking for 2,500,000 EUR in investment. Interested investors please contact Dr.Gregory Penner at gpenner@neoneuro-aptamers.com

www.neoneuro-aptamers.com